hrp0094p2-67 | Bone, growth plate and mineral metabolism | ESPE2021

X-linked hypophosphatemic rickets caused by a large deletion in PHEX gene in a Brazilian family

Chini Larissa , Cabral Larissa , Cavalieri Marilene , Isaac Alvaro , Carneiro Zumira , Hirose Thiago , Lourenco Charles ,

Background: X linked hypophosphatemic rickets (XLHR; OMIM 307800) is an X linked dominant disorder caused by mutations in the phosphate regulating neutral endopeptidase homolog X linked (PHEX) gene, which is located at Xp22.11.Objective: To clarify the underlying mechanism of a Brazilian family with hypophosphatemic rickets whose clinical manifestations were very broad among members of different generations.<p class=...

hrp0097rfc10.3 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) &amp; Multisystem endocrine disorders | ESPE2023

Non-coding Variants in HK1 Account for 5% of Cases of Congenital Hyperinsulinism Without an Identified Genetic Cause

Rosenfeld Elizabeth , E. Boodhansingh Kara , A. Stanley Charles , Ganguly Arupa , D. De Leon Diva

Background: The genetic etiology of non-syndromic HI remains unknown in over 20% of all cases, and over 50% of diazoxide-responsive cases. Non-coding variants in HK1 have been suggested to cause HI by linkage-analysis (Pinney et al., 2008). More recently, variants within a regulatory region of HK1 intron 2 were reported in 17 individuals with HI (Wakeling et al., 2022). These variants have been proposed to cause HI by disrup...

hrp0097p1-191 | Thyroid | ESPE2023

Paediatric Graves’ Disease: Presentation, Treatment and Follow up. A Single Centre Experience from United Kingdom.

Vijayan Roopa , Kapoor Ritika , Agrawal Pankaj , Buchanan Charles , Chapman Simon , Arya Ved

Objective: To describe a cohort with paediatric Graves disease followed between 2012 and 2022 at King’s College Hospital, London.Materials and Methods: Retrospective study of 36 patients treated with block and replace regimen of anti-thyroid drugs with a median (range) follow up of 4.25 (1.1-10.8) years. Demographic, clinical, biochemical and treatment data were collected from clinical records. Predictive factors f...

hrp0097p1-395 | Thyroid | ESPE2023

Thyroid Storm with Diabetes Insipidus: Management of A Rare Endocrine Presentation In A Child

Agrawal Pankaj , R Kapoor Ritika , R Buchanan Charles , Bhushan Arya Ved

Introduction: Thyroid storm is an acute, life-threatening, emergency in children with thyrotoxicosis. It is extremely rare and could be an initial presentation in previously undiagnosed children. Thyroid storm with diabetes insipidus (DI) has been reported in adults, but no cases have been reported in children. We herein report a child with thyroid storm with transient central DI.Case Report: A 7-year-old girl, presented...

hrp0097p2-144 | Growth and Syndromes | ESPE2023

Beyond the surface: A Tale of Uncovering the True Diagnosis

Vijayan Roopa , Fox Krystal , Parmar Hannah , Kapoor Ritika , Buchanan Charles , Bhushan Arya Ved

Introduction: In a large series, approximately 65% of boys with delayed puberty have constitutional delay in growth and puberty (CDGP). We report an adolescent male who presented with delayed puberty and managed as presumed CDGP. Unexpected pubertal progression while receiving treatment made us question the diagnosis of CDGP.Case-report: A 15-year-old African adolescent male presented with delayed growth and puberty. He ...

hrp0089p2-p233 | GH &amp; IGFs P2 | ESPE2018

Effects of Zinc, Magnesium and Vitamin B6 (ZMA) Supplementation on Serum IGF-I, IGFBP-3 and Testosterone Concentrations in Young Athletes

Cerqueira Henrique , Tourinho Filho Hugo , Martinelli Jr Carlos

Background: The GH-IGF system plays an important role in strength gain. Some studies suggest that Zinc, Magnesium and Pyridoxine (ZMA) supplementation could increase GH/IGF and testosterone levels in young subjects. This hypothetical increase could lead to significant changes in body composition. ZMA is a very popular supplement, easily found in specialty stores, and it is presumed to increase GH, IGF-I and testosterone levels. However, studies are divergent regarding its effi...

hrp0089p3-p358 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P3 | ESPE2018

Argentinean First Experience with Transgender Children and Youths

Figueroa Veronica , Dacal Jimena Lopez , Sanz Carlos , Brunetto Oscar

Introduction: During last years there is an increasing number of referrals because of gender incongruence worldwide. In Argentina, in 2012, a gender identity law was sanctioned, stablishing the right of gender reassignment during childhood, adolescence, youth and adulthood, without the need of previous medical and/or mental health evaluation. This was followed by a great number of referrals. There is scarce literature regarding longterm outcome in transgender persons who start...

hrp0084p2-208 | Bone | ESPE2015

Bone Mineral Density in Children and Adolescents with Vertical HIV Infection

Vargas Deisi Maria , Prust Daniela Oliveira , Galvao Jose Carlos

Background: Chronic diseases are the main causes of bone mass reduction in childhood and adolescence. Different aspects related to the process of bone acquisition and maintenance may be affected. Studies had point out the presence of bone mass reduction in children and adolescents with HIV infection with association to antiretroviral use, chronological age (CA), weight and serum CD4 T-cell counts. However, others do not.Objective: To evaluate bone minera...

hrp0084p3-966 | GH &amp; IGF | ESPE2015

GH Treatment and First Year Response: A Retrospective Study

Moniz Catarina , Vasconcelos Carlos , Limbert Clotilde , Saraiva Catarina

Background: GH treatment is proven to increase adult final height in some pathology and first year response is assumed as an index of treatment’s effectiveness.Objective and hypotheses: Identify the prevalence of each indication in children treated with GH in our hospital and evaluate the first year response to treatment.Method: We retrospectively analysed the files of 30 patients followed for short stature and on GH treatment...

hrp0092p2-277 | Thyroid | ESPE2019

Congenital Hypothyroidism: Neonatal SCREENING PROGRAM with T4 and TSH

Chueca Maria J. , Moreno Paula , Dura Teodoro , Berrade Sara , Andres Carlos , Garcia Maria Dolores , Moreno Jose Carlos , Ascunce Nieves

Objectives: -To determine children diagnosed with central congenital hypothyroidism (CCH) by a screening program using TSH and total T4 between May 2016 and January 2019.-To analyze the characteristics of the disease in these children.Material and Methods: During the time of the study, 14.743 newborns have been screened. Cut-off points are used for TSH ≥10MU/ml and T4 6 and 20 mg/dl as lower ...